Literature DB >> 15776250

Extensively high load of internal tumors determined by whole body MRI scanning in a patient with neurofibromatosis type 1 and a non-LCR-mediated 2-Mb deletion in 17q11.2.

Hildegard Kehrer-Sawatzki1, Lan Kluwe, Carsten Fünsterer, Victor-Felix Mautner.   

Abstract

Deletions in 17q11.2 affecting the NF1 gene and surrounding regions occur in 5% of patients with NF1. The two major types of NF1 deletions encompass 1.4-Mb and 1.2-Mb, respectively, and have breakpoints in the NF1 low-copy repeats or in the JJAZ gene and its pseudogene. Deletions larger than 1.4-Mb are rare, and only seven cases have been reported so far. Here, we describe a 26-year-old NF1 patient with an "atypical" NF1 deletion of 2-Mb. In contrast to the 1.4-Mb deletions, which preferentially occur by interchromosomal recombination during maternal meiosis, the deletion described here occurred intrachromosomally on the paternal chromosome. The centromeric deletion breakpoint lies in an L1-element located 1.3-Mb proximal to the NF1 gene. The telomeric deletion boundary is located in a single copy segment between an AT-rich segment and an AluSx-element in intron 15 of the JJAZ1 gene. Structural analysis implies that non-B DNA conformations at the breakpoints destabilized the duplex DNA and caused double-strand breaks. Although the breakpoints of this 2-Mb deletion are not recurrent, it is conspicuous that one breakpoint is located in the JJAZ1 gene. Paralogous recombination between the JJAZ1 gene and its pseudogene causes the recurrent 1.2 Mb deletions. The genomic architecture of the NF1 gene region, influenced by paralogous sequences such as the JJAZ1 gene and its pseudogene, seems also to stimulate the occurrence of non-recurrent deletions mediated by non-homologous end joining. Patient 442 described here suffers from a very high burden of subdermal neurofibromas. Magnetic resonance imaging of the whole body revealed numerous internal tumors, mainly plexiform neurofibromas and spinal tumors. This demonstrates the value of whole-body MRI scanning in determining the total tumor load, which is an important aspect in genotype/phenotype correlations with regard to large NF1 deletions.

Entities:  

Mesh:

Year:  2005        PMID: 15776250     DOI: 10.1007/s00439-005-1265-4

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  32 in total

1.  A common set of at least 11 functional genes is lost in the majority of NF1 patients with gross deletions.

Authors:  D E Jenne; S Tinschert; E Stegmann; H Reimann; P Nürnberg; D Horn; I Naumann; A Buske; G Thiel
Journal:  Genomics       Date:  2000-05-15       Impact factor: 5.736

2.  Mental retardation and cardiovascular malformations in NF1 microdeleted patients point to candidate genes in 17q11.2.

Authors:  M Venturin; P Guarnieri; F Natacci; M Stabile; R Tenconi; M Clementi; C Hernandez; P Thompson; M Upadhyaya; L Larizza; P Riva
Journal:  J Med Genet       Date:  2004-01       Impact factor: 6.318

3.  Evidence for non-homologous end joining and non-allelic homologous recombination in atypical NF1 microdeletions.

Authors:  Marco Venturin; Cristina Gervasini; Francesca Orzan; Angela Bentivegna; Lucia Corrado; Patrizia Colapietro; Alessandra Friso; Romano Tenconi; Meena Upadhyaya; Lidia Larizza; Paola Riva
Journal:  Hum Genet       Date:  2004-04-21       Impact factor: 4.132

4.  Identification of de novo deletions at the NF1 gene: no preferential paternal origin and phenotypic analysis of patients.

Authors:  M C Valero; I Pascual-Castroviejo; E Velasco; F Moreno; C Hernández-Chico
Journal:  Hum Genet       Date:  1997-06       Impact factor: 4.132

5.  Treatment of ADHD in neurofibromatosis type 1.

Authors:  Victor-F Mautner; Lan Kluwe; Sarang D Thakker; Robert A Leark
Journal:  Dev Med Child Neurol       Date:  2002-03       Impact factor: 5.449

6.  Deletion of the entire NF1 gene causing distinct manifestations in a family.

Authors:  B L Wu; G H Schneider; B R Korf
Journal:  Am J Med Genet       Date:  1997-03-03

7.  Familial neurofibromatosis 1 microdeletions: cosegregation with distinct facial phenotype and early onset of cutaneous neurofibromata.

Authors:  K A Leppig; P Kaplan; D Viskochil; M Weaver; J Ortenberg; K Stephens
Journal:  Am J Med Genet       Date:  1997-12-12

8.  Elevated risk for MPNST in NF1 microdeletion patients.

Authors:  T De Raedt; H Brems; P Wolkenstein; D Vidaud; S Pilotti; F Perrone; V Mautner; S Frahm; R Sciot; E Legius
Journal:  Am J Hum Genet       Date:  2003-03-26       Impact factor: 11.025

9.  Large de novo DNA deletion in a patient with sporadic neurofibromatosis 1, mental retardation, and dysmorphism.

Authors:  L M Kayes; V M Riccardi; W Burke; R L Bennett; K Stephens
Journal:  J Med Genet       Date:  1992-10       Impact factor: 6.318

10.  Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene.

Authors:  Lan Kluwe; Reiner Siebert; Stefan Gesk; Reinhard E Friedrich; Sigrid Tinschert; Hildegard Kehrer-Sawatzki; Victor-F Mautner
Journal:  Hum Mutat       Date:  2004-02       Impact factor: 4.878

View more
  12 in total

1.  Conventional and functional MR imaging of peripheral nerve sheath tumors: initial experience.

Authors:  S Demehri; A Belzberg; J Blakeley; L M Fayad
Journal:  AJNR Am J Neuroradiol       Date:  2014-04-24       Impact factor: 3.825

Review 2.  On the sequence-directed nature of human gene mutation: the role of genomic architecture and the local DNA sequence environment in mediating gene mutations underlying human inherited disease.

Authors:  David N Cooper; Albino Bacolla; Claude Férec; Karen M Vasquez; Hildegard Kehrer-Sawatzki; Jian-Min Chen
Journal:  Hum Mutat       Date:  2011-09-02       Impact factor: 4.878

3.  Type 2 NF1 deletions are highly unusual by virtue of the absence of nonallelic homologous recombination hotspots and an apparent preference for female mitotic recombination.

Authors:  Katharina Steinmann; David N Cooper; Lan Kluwe; Nadia A Chuzhanova; Cornelia Senger; Eduard Serra; Conxi Lazaro; Montserrat Gilaberte; Katharina Wimmer; Viktor-Felix Mautner; Hildegard Kehrer-Sawatzki
Journal:  Am J Hum Genet       Date:  2007-10-31       Impact factor: 11.025

4.  The spectrum of somatic and germline NF1 mutations in NF1 patients with spinal neurofibromas.

Authors:  Meena Upadhyaya; Gill Spurlock; Lan Kluwe; Nadia Chuzhanova; Emma Bennett; Nick Thomas; Abhijit Guha; Victor Mautner
Journal:  Neurogenetics       Date:  2009-02-17       Impact factor: 2.660

5.  Dissecting the clinical phenotype associated with mosaic type-2 NF1 microdeletions.

Authors:  Hildegard Kehrer-Sawatzki; Julia Vogt; Tanja Mußotter; Lan Kluwe; David N Cooper; Victor-Felix Mautner
Journal:  Neurogenetics       Date:  2012-05-13       Impact factor: 2.660

6.  Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

Authors:  Victor-F Mautner; Florence A Asuagbor; Eva Dombi; Carsten Fünsterer; Lan Kluwe; Ralf Wenzel; Brigitte C Widemann; Jan M Friedman
Journal:  Neuro Oncol       Date:  2008-06-17       Impact factor: 12.300

7.  Safe marginal resection of atypical neurofibromas in neurofibromatosis type 1.

Authors:  Charlie N Nelson; Eva Dombi; Jared S Rosenblum; Markku M Miettinen; Tanya J Lehky; Patricia O Whitcomb; Christina Hayes; Gretchen Scott; Sarah Benzo; Brigitte C Widemann; Prashant Chittiboina
Journal:  J Neurosurg       Date:  2019-10-25       Impact factor: 5.115

8.  Screening for mutation site on the type I neurofibromatosis gene in a family.

Authors:  Ming Lv; Wenhua Zhao; Lin Yan; Liang Chen; Kai Cui; Jie Gao; Fachang Yu; Sheng Li
Journal:  Childs Nerv Syst       Date:  2011-12-30       Impact factor: 1.475

9.  Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions.

Authors:  Tanja Mußotter; Lan Kluwe; Josef Högel; Rosa Nguyen; David N Cooper; Victor-Felix Mautner; Hildegard Kehrer-Sawatzki
Journal:  BMC Med Genet       Date:  2012-10-26       Impact factor: 2.103

10.  Whole Body MRI at 3T with Quantitative Diffusion Weighted Imaging and Contrast-Enhanced Sequences for the Characterization of Peripheral Lesions in Patients with Neurofibromatosis Type 2 and Schwannomatosis.

Authors:  Laura M Fayad; Jaishri Blakeley; Scott Plotkin; Brigitte Widemann; Michael A Jacobs
Journal:  ISRN Radiol       Date:  2013-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.